In Vivo Noninvasive Imaging for Gene Therapy
Overview
Authors
Affiliations
Gene therapy is reaching a stage where some clinical benefits have been demonstrated on patients involved in phase I/II clinical trials. However, in many cases, the clinical benefit is hardly measurable and progress in the improvement of gene therapy formulations is hampered by the lack of objective clinical endpoints to measure transgene delivery and to quantitate transgene expression. However, these endpoints rely almost exclusively on the analysis of biopsies by molecular and histopathological methods. These methods provide only a limited picture of the situation. Therefore, there is a need for a technology that would allow precise, spacio-temporal measurement of gene expression on a whole body scale upon administration of the gene delivery vector. In the field of gene therapy, a considerable effort is being invested in the development of noninvasive imaging of gene expression and this review presents the various strategies currently being developed.
Synthesis of Radioiodinated Compounds. Classical Approaches and Achievements of Recent Years.
Petrov S, Yusubov M, Beloglazkina E, Nenajdenko V Int J Mol Sci. 2022; 23(22).
PMID: 36430267 PMC: 9698107. DOI: 10.3390/ijms232213789.
Theranostic nanoparticles for the management of thrombosis.
Russell P, Hagemeyer C, Esser L, Voelcker N Theranostics. 2022; 12(6):2773-2800.
PMID: 35401833 PMC: 8965493. DOI: 10.7150/thno.70001.
Theranostic potential of oncolytic vaccinia virus.
Rojas J, Thorne S Theranostics. 2012; 2(4):363-73.
PMID: 22509200 PMC: 3326721. DOI: 10.7150/thno.3724.
Merron A, Baril P, Martin-Duque P, De la Vieja A, Tran L, Briat A Eur J Nucl Med Mol Imaging. 2010; 37(7):1377-85.
PMID: 20140612 DOI: 10.1007/s00259-009-1379-3.
Baril P, Martin-Duque P, Vassaux G Br J Pharmacol. 2009; 159(4):761-71.
PMID: 19814733 PMC: 2829202. DOI: 10.1111/j.1476-5381.2009.00412.x.